重度哮喘患者美泊利单抗治疗真实世界4年回顾性分析数据集
重度哮喘患者接受美泊利单抗治疗4年的真实世界回顾性队列数据，包括恶化、OCS使用和医疗资源利用及费用。
基本信息
资源简介
重度哮喘患者美泊利单抗治疗真实世界4年回顾性分析数据集
【一句话概览】
本数据集是 figshare 公开的结构化表格数据集，收录 3 个文件、合计 853.87 KB，主题涵盖 Adherence、persistence、long-term、effectiveness，可用于统计建模、特征工程与队列分析，CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retrospective analysis》。配套论文《Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retrospective analysis》发表于 Journal of Asthma（2025），DOI：10.1080/02770903.2025.2450640。项目资助方：This study was funded by GSK [GSK ID: 217456]. The sponsor was involved in study design and implementation, as well as data collection, analysis, interpretation, writing the study report and reviewing this manuscript. The sponsor did not place any restrictions on access to data or statements made in the manuscript. All authors had full access to the data upon request and had final responsibility for the decision to submit for publication.。源站首次发布：2025-01-22。
【数据内容】
源站原始描述：Although the efficacy of mepolizumab in reducing exacerbations and oral corticosteroid (OCS) use in severe asthma is well-established, real-world long-term effectiveness data are limited. This study evaluated the real-world impact of mepolizumab treatment in patients with severe asthma over a 4-year follow-up period. This was a retrospective cohort study of patients with asthma initiating mepolizumab (index date: first claim, November 2015–September 2019) using the Merative MarketScan Commercial…
【数据结构与技术规格】
文件数 3 个，合计 853.87 KB。ijas_a_2450640_sm3947.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，73.71 KB。ijas_a_2450640_sm3946.pdf：application/pdf，373.10 KB。ijas_a_2450640_sm3944.pdf：application/pdf，407.06 KB。数据集 DOI：10.6084/m9.figshare.28174827.v2。
【主题与分类】
源站学科分类：Medicine、Ecology、Immunology、Statistics、Science Policy、Infectious Diseases。主题标签：Adherence、persistence、long-term、effectiveness。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面：https://tandf.figshare.com/articles/dataset/Real-world_mepolizumab_treatment_in_patients_with_severe_asthma_decreased_exacerbations_oral_corticosteroid_use_and_healthcare_resource_utilization_and_costs_over_4_years_a_retrospective_analysis/28174827
使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。
规范引用：Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retrospective analysis. Taylor & Francis. Moore, Wendy C.; Stach-Klysh, Alexandra; Corbridge, Thomas; Packnett, Elizabeth; M…
【使用注意】
· 源站最后修改于 2025-05-20，引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务（收技术服务费，非数据销售）
暂未开放当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取（Figshare）
- 源站标题：Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retrospective analysis
- DOI：10.6084/m9.figshare.28174827.v2
- 发布日期：2025-01-22
- 文件数：3 个
- 文件总体积：853.87 KB
- 源站页面：https://tandf.figshare.com/articles/dataset/Real-world_mepolizumab_treatment_in_patients_with_severe_asthma_decreased_exacerbations_oral_corticosteroid_use_and_healthcare_resource_utilization_and_costs_over_4_years_a_retrospective_analysis/28174827
命令行下载
curl -L -o "ijas_a_2450640_sm3947.docx" "https://ndownloader.figshare.com/files/51574194"
curl -L -o "ijas_a_2450640_sm3946.pdf" "https://ndownloader.figshare.com/files/51574197"
curl -L -o "ijas_a_2450640_sm3944.pdf" "https://ndownloader.figshare.com/files/51574203"
文件清单
ijas_a_2450640_sm3947.docx（73.71 KB）ijas_a_2450640_sm3946.pdf（373.10 KB）ijas_a_2450640_sm3944.pdf（407.06 KB）
文件总体积 853.87 KB（源站 API 实测）。
数据加载示例（图像类）
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
数据说明
Although the efficacy of mepolizumab in reducing exacerbations and oral corticosteroid (OCS) use in severe asthma is well-established, real-world long-term effectiveness data are limited. This study evaluated the real-world impact of mepolizumab treatment in patients with severe asthma over a 4-year follow-up period.
This was a retrospective cohort study of patients with asthma initiating mepolizumab (index date: first claim, November 2015–September 2019) using the Merative MarketScan Commercial and Medicare Databases. Outcomes included asthma exacerbations, OCS use, and exacerbation-related healthcare resource utilization (HCRU) and costs, assessed 12-months pre-index (baseline) and annually during the 4-year follow-up period.
Among 189 eligible patients, mean asthma exacerbation rate (AER) declined progressively from baseline during follow-up: AER decreased by 53.8% at Year 1 and 73.8% by Year 4 (p p p Patients treated with mepolizumab demonstrated progressive and sustained long-term, real-world reductions in exacerbation frequency, OCS dependency, and exacerbation-related HCRU and costs over 4 years.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.6084/m9.figshare.28174827.v2（source: https://tandf.figshare.com/articles/dataset/Real-world_mepolizumab_treatment_in_patients_with_severe_asthma_decreased_exacerbations_oral_corticosteroid_use_and_healthcare_resource_utilization_and_costs_over_4_years_a_retrospective_analysis/28174827）。
数据缺失？
依托陕西、四川两大基地，我们与超过十家三甲医院建立直接合作关系，覆盖合规授权、采集治理、专业标注、数据交付的全流程，为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务？立即联系我们获取专业方案。
